Novo Nordisk A/S ADR Stock
€42.55
Your prediction
Novo Nordisk A/S ADR Stock
Pros and Cons of Novo Nordisk A/S ADR in the next few years
Pros
Cons
Performance of Novo Nordisk A/S ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR | 0.000% | -1.845% | -8.691% | -56.134% | -49.103% | -61.318% | -25.351% |
| Bayer AG ADR | -0.750% | -2.190% | 3.077% | 34.000% | 35.081% | -48.462% | -41.739% |
| Roche Holding AG ADR | -0.390% | 7.934% | 9.203% | 25.878% | 26.519% | 8.697% | 19.428% |
| Astrazeneca ADR | 0.650% | 1.974% | 6.164% | 28.099% | 21.094% | 22.627% | 70.705% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Novo Nordisk, recognized as a pivotal player in the Pharmaceuticals industry, particularly in diabetes and obesity care, showcases a robust financial profile as reflected in its recent statements. With significant growth in revenue and earnings, the financial indicators exhibit both strength and potential challenges. This analysis dives deep into the profits, liabilities, and other aspects that paint a comprehensive picture of the company.
Overview of Financial Performance
The fiscal year 2023 has been noteworthy for Novo Nordisk, with total revenue reaching approximately DKK 232.26 billion. The net income for the same period stands at DKK 83.68 billion, translating into a profit margin of 36.55%. This level of profitability indicates a healthy operational framework, allowing the company to maintain a solid position within a competitive market.
Comments
News
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) and reminds investors of the September
